AAP
BEAM icon

Arax Advisory Partners’s Beam Therapeutics BEAM Stock Holding History

Arax Advisory Partners’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$238 Sell
10
-65
-87% -$1.8K ﹤0.01% 3515
2025
Q4 		$2.08K Buy
+75
New +$1.91K ﹤0.01% 3244
2025
Q2 		– Sell
-30
Closed -$586 – 3049
2025
Q1 		$586 Hold
30
– – ﹤0.01% 2514
2024
Q4 		$744 Buy
+30
New +$766 ﹤0.01% 2235

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Arax Advisory Partners's BEAM Position: Q1 2026 in Review

Arax Advisory Partners reduced its Beam Therapeutics (BEAM) stake by 87% in Q1 2026, selling an estimated $1.8K and leaving 10 shares worth $238. The position accounts for ﹤0.01% of the portfolio, ranked #3515.

Arax Advisory Partners first reported a position in BEAM in Q4 2024 and has held it in 4 quarters since. The position peaked at $2.08K in Q4 2025. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Arax Advisory Partners held 10 shares of Beam Therapeutics worth $238 as of Q1 2026.
  • Arax Advisory Partners sold 65 Beam Therapeutics shares in Q1 2026, an estimated $1.8K.
  • Beam Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3515 holding.
  • Arax Advisory Partners first reported a position in Beam Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Arax Advisory Partners's Beam Therapeutics position peaked at $2.08K in Q4 2025.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.